Alexion Archives -

AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

Last year, AstraZeneca reported that a new drug to treat Wilson disease developed by its Alexion rare diseases

Data backs AZ’s Wilson disease drug, but with a question mark

https://pharmaphorum.com/news/data-backs-azs-wilson-disease-drug-but-with-a-question-mark/

R&D/ Views & Analysis/ Views and analysis

Big pharma vs small diseases: Tackling rare diseases

Jonah Comstock Alexion, Novo Nordisk, pharma, rare disease 0 Comment

Rare diseases aren’t as rare as the appellation suggests. For instance, according to the US Government Accountability Office,

Big pharma vs small diseases: Tackling rare diseases

https://pharmaphorum.com/r-d/big-pharma-vs-small-diseases-tackling-rare-diseases/

News/ News/ Sales and Marketing

AZ pays $775m to settle patent dispute with Chugai over Ultomiris

Phil Taylor Alexion, AstraZeneca, Chugai, patent litigation, Roche, Ultomiris 0 Comment

AstraZeneca has resolved a lingering liability following its takeover of Alexion with an agreement to pay $775 million

AZ pays $775m to settle patent dispute with Chugai over Ultomiris

https://pharmaphorum.com/news/az-pays-775m-to-settle-patent-dispute-with-chugai-over-ultomiris/

Market Access/ News/ News

EU gives narrower label to Apellis, Sobi’s PNH drug

Phil Taylor Alexion, Apellis Pharma, Aspaveli, AstraZeneca, Empaveli, paroxysmal nocturnal haemoglobinuria, pegcetacoplan, rare disease, regulatory approval, SOBI, Soliris, Ultomiris 0 Comment

Apellis Pharma and partner Sobi have won EU approval for their paroxysmal nocturnal haemoglobinuria (PNH) drug pegcetacoplan in

EU gives narrower label to Apellis, Sobi’s PNH drug

https://pharmaphorum.com/news/eu-gives-narrower-label-to-apellis-sobis-pnh-drug/

News/ News/ R&D

AZ claims full control of Caelum’s AL amyloidosis drug in $500m deal

Phil Taylor AL amyloidosis, Alexion, AstraZeneca, Caelum Biosciences, M&A, rare disease 0 Comment

AstraZeneca’s newly acquired Alexion will buy the remaining equity in rare disease specialist Caelum Biosciences in a deal

AZ claims full control of Caelum’s AL amyloidosis drug in $500m deal

https://pharmaphorum.com/news/az-claims-full-control-of-caelums-al-amyloidosis-drug-in-500m-deal/

News/ News/ R&D

After Ultomiris stumble, Alexion delivers a rare disease win for AZ

Phil Taylor Alexion, AstraZeneca, rare disease, Wilson disease 0 Comment

A drug for Wilson disease developed by AstraZeneca’s Alexion rare disease unit has cleared a phase 3 trial,

After Ultomiris stumble, Alexion delivers a rare disease win for AZ

https://pharmaphorum.com/news/after-ultomiris-stumble-alexion-delivers-a-rare-disease-win-for-az/

News/ News/ R&D

AZ’s Alexion plans hit a snag as Ultomiris flunks ALS trial

Phil Taylor Alexion, amyotrophic lateral sclerosis, AstraZeneca, complement therapeutics, neurodegenerative disease, Soliris, UCB, Ultomiris, zilucoplan 0 Comment

It has only been a month since AstraZeneca’s $39 billion takeover of Alexion was completed, but the new

AZ’s Alexion plans hit a snag as Ultomiris flunks ALS trial

https://pharmaphorum.com/news/azs-alexion-takeover-hits-a-snag-as-ultomiris-flunks-als-trial/

Market Access/ News/ News

Boost for AZ as Ultomiris gets CHMP nod for expanded label

Phil Taylor Alexion, AstraZeneca, Kyowa Kirin, Nexviadyme, Nouryant, Parkinson's disease, Pompe disease, rare disease, Sanofi Genzyme, Soliris, Ultomiris 0 Comment

Fresh from its takeover of Alexion, AstraZeneca has picked up a recommendation in the EU for an expansion

Boost for AZ as Ultomiris gets CHMP nod for expanded label

https://pharmaphorum.com/news/boost-for-az-as-ultomiris-gets-chmp-nod-for-expanded-label/

News/ News/ Sales and Marketing

Final hurdle falls as UK backs AZ’s $39bn takeover of Alexion

Phil Taylor Alexion, AstraZeneca, Financial, immunology, M&A, rare disease, regulatory 0 Comment

The UK’s competition regulator has approved AstraZeneca’s $39 billion acquisition of US-based drugmaker Alexion, without opting for a

Final hurdle falls as UK backs AZ’s $39bn takeover of Alexion

https://pharmaphorum.com/news/final-hurdle-falls-as-uk-backs-azs-39bn-takeover-of-alexion/

Trending

Alexion

Login